345 related articles for article (PubMed ID: 15252144)
21. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
22. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.
Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y
J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440
[TBL] [Abstract][Full Text] [Related]
24. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.
Chang H; Rha SY; Jeung HC; Im CK; Ahn JB; Kwon WS; Yoo NC; Roh JK; Chung HC
Ann Oncol; 2009 Feb; 20(2):272-7. PubMed ID: 18836089
[TBL] [Abstract][Full Text] [Related]
25. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer.
Risnayanti C; Jang YS; Lee J; Ahn HJ
Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419
[TBL] [Abstract][Full Text] [Related]
26. Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.
Eyre R; Harvey I; Stemke-Hale K; Lennard TW; Tyson-Capper A; Meeson AP
Tumour Biol; 2014 Oct; 35(10):9879-92. PubMed ID: 24993095
[TBL] [Abstract][Full Text] [Related]
27. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multi-drug resistance by vector-based-shRNA-mdr1 in vitro and in vivo.
Lu S; Huang Q; Wang Z; Song Y; Wang L
J Huazhong Univ Sci Technolog Med Sci; 2009 Oct; 29(5):620-4. PubMed ID: 19821097
[TBL] [Abstract][Full Text] [Related]
29. [Reversal of multi-drug resistance in ovarian cancer cell by RNA interference].
Lou JY; Peng ZL; Zheng Y; Wang H; He B; Wang HJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):413-6. PubMed ID: 16831368
[TBL] [Abstract][Full Text] [Related]
30. The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
Zhang H; Patel A; Wang YJ; Zhang YK; Kathawala RJ; Qiu LH; Patel BA; Huang LH; Shukla S; Yang DH; Ambudkar SV; Fu LW; Chen ZS
Mol Cancer Ther; 2017 Jun; 16(6):1021-1030. PubMed ID: 28265007
[TBL] [Abstract][Full Text] [Related]
31. Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-α) with small interference RNA (siRNA) agents.
Zhao LJ; Xu H; Qu JW; Zhao WZ; Zhao YB; Wang JH
Asian Pac J Cancer Prev; 2012; 13(8):3631-6. PubMed ID: 23098446
[TBL] [Abstract][Full Text] [Related]
32. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
[TBL] [Abstract][Full Text] [Related]
33. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Ludwig JA; Szakács G; Martin SE; Chu BF; Cardarelli C; Sauna ZE; Caplen NJ; Fales HM; Ambudkar SV; Weinstein JN; Gottesman MM
Cancer Res; 2006 May; 66(9):4808-15. PubMed ID: 16651436
[TBL] [Abstract][Full Text] [Related]
34. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
35. hMSH2 expression is associated with paclitaxel resistance in ovarian carcinoma, and inhibition of hMSH2 expression in vitro restores paclitaxel sensitivity.
Zhang J; Yin D; Li H
Oncol Rep; 2014 Nov; 32(5):2199-206. PubMed ID: 25175513
[TBL] [Abstract][Full Text] [Related]
36. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
[TBL] [Abstract][Full Text] [Related]
37. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
[TBL] [Abstract][Full Text] [Related]
38. Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1/ABCB4.
Gautherot J; Durand-Schneider AM; Delautier D; Delaunay JL; Rada A; Gabillet J; Housset C; Maurice M; Aït-Slimane T
J Biol Chem; 2012 Feb; 287(7):5070-8. PubMed ID: 22184139
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.
Shimomura M; Yaoi T; Itoh K; Kato D; Terauchi K; Shimada J; Fushiki S
Int J Oncol; 2012 Apr; 40(4):995-1004. PubMed ID: 22179563
[TBL] [Abstract][Full Text] [Related]
40. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
